FDA compounding review On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 (free base) and AOD-9604 acetate against the 503A Bulks List
Do not transfer doses across routes
When used appropriately under physician guidance as part of comprehensive metabolic optimization strategies, AOD-9604 may provide a research-based tool for individuals committed to evidence-informed approaches to body composition improvement
Subjects showed enhanced energy metabolism, reduced body fat, and improved insulin sensitivity
Injection-site reactions: Mild redness, tenderness or irritation
This high-concentration format provides 1,000MG total 5-Amino-1MQ in a finished cGMP research solution for researchers studying NNMT-associated metabolic signaling and cellular energy pathway behavior under controlled laboratory conditions